The efficacy and safety of zanubrutinib combined with BR regimen in B-cell chronic lymphoproliferative disorder
10.12025/j.issn.1008-6358.2026.20251340
- VernacularTitle:泽布替尼联合BR方案治疗B细胞慢性淋巴增殖性疾病的效果及安全性
- Author:
Danxia LIN
1
;
Zhihong JIANG
1
;
Xiaona WANG
1
;
Yating JIANG
1
;
Yangyang WANG
1
;
Yuxin ZHANG
1
;
Zheng WEI
2
Author Information
1. Department of Hematology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen Clinical Research Center for Cancer Therapy, Clinical Research Center for Precision Medicine of Abdominal Tumor of Fujian Province, Xiamen 361015, Fujian, China.
2. Department of Hematology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen Clinical Research Center for Cancer Therapy, Clinical Research Center for Precision Medicine of Abdominal Tumor of Fujian Province, Xiamen 361015, Fujian, China;Clinical Center for Biotherapy, Zhongshan Hospital (Xiamen), Fudan University, Xiamen Key Laboratory of Biotherapy, Xiamen 361015, Fujian, China;Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Publication Type:Shortarticle
- Keywords:
B-cell chronic lymphoproliferative disorder;
non-Hodgkin lymphoma;
zanubrutinib;
BR regimen
- From:
Chinese Journal of Clinical Medicine
2026;33(4):651-660
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of a zanubrutinib-based combination regimen as first-line treatment for patients with B-cell chronic lymphoproliferative disorder (B-CLPD). Methods A retrospective analysis was performed on 26 patients with B-CLPD, including indolent B-cell non-Hodgkin lymphoma (B-iNHL), mantle cell lymphoma (MCL), and other unclassifiable B-CLPD, who were newly diagnosed and treated at the Department of Hematology, Zhongshan Hospital (Xiamen), Fudan University between January 2021 and January 2025. Patients were divided into two groups according to the treatment regimen: BR (bendamustine plus rituximab) and ZBR (zanubrutinib combined with BR regimen). Baseline characteristics, treatment responses, and the incidence of treatment-related adverse events (TRAE) were compared between the two groups. Results No statistically significant differences in baseline characteristics were observed between the two groups. All patients completed at least four cycles of treatment. There were no significant differences between the BR and ZBR groups in partial response rate (46.2% vs 53.8%), complete response rate (53.8% vs 15.4%), overall response rate (100.0% vs 84.6%), or TRAE incidence. After the first cycle, the lymphocyte count was higher in the ZBR group than in the BR group (P＝0.002); no other statistically significant differences in other hematologic parameters were observed at any treatment cycle. Conclusions In patients with B-iNHL, MCL, and other unclassifiable B-CLPD, the ZBR regimen demonstrates similar safety and response rates to the BR regimen. These findings support further investigation into the clinical value of ZBR as first-line treatment regimen in a limited course for indolent lymphoid malignancies.
